新疆地区1998至2008年结核分枝杆菌耐药情况分析
李君莲,魏继虎,綦迎成,王泉,李东军,胡忠义,金格勒,刘天剑,刘艳李君莲、綦迎成、王泉、刘天剑、刘艳,乌鲁木齐,新疆维吾尔自治区胸科医院检验科,830049;魏继虎、金格勒,新疆医科大学第一附属医院骨科,830049;李东军,乌鲁木齐急救中心,830049;胡忠义,同济大学附属肺科医院 上海市结核重点实验室,830049
基金项目: 上海市结核病重点实验室开放基金(2009-09)
摘 要:目的 了解新疆地区1998~2008年结核分枝杆菌耐药情况,为新疆地区结核病的诊断、治疗以及防控提供参考。方法 用 BACTEC MGIT-960系统对不同来源的临床标本进行药物敏感试验。结果 总耐药率、耐链霉素率、耐利福平率由1998年的78.20%、44.14%、44.68%降低到2008年的59.62%、27.64%、21.05%;耐乙胺丁醇率由1998年的14.23%升高到2008年的21.68%;耐异烟肼变化不大。耐1种药由1998年的35.86%降到2008年的31.44%,耐4种药由1998年的0.54%升高到2008年的2.08%。结论 尽管新疆地区的耐药率仍高于全国平均水平,但11年来耐药率呈下降趋势,耐多药结核病增多应引起高度重视。
关键词:分枝杆菌,结核; 广泛耐药结核; 微生物敏感性试验
Analysis on drug resistance of Mycobacterium tuberculosis during 1998~2008 in Xinjiang
LI Jun-lian,WEI Ji-hu,QI Ying-cheng,WANG Quan,LI Dong-jun,HU Zhong-yi,JIN Ge-le,LIU Tian-jian, LIU Yan.The Chest Hospital of Xinjiang Uygur Autonomous Region,Urumchi 830049,China
Abstract:Objective To analyze the current situation of drug resistance of Mycobacterium tuberculosis in Xinjiang and to provide information for diagnosis,treatment and policy on tuberculosis (TB) control.Methods Mycobacterium tuberculosis susceptibility tests were done by BACTEC MGIT-960 cultural and drug susceptibility testing system.Results The rates of total drug resistance,drug resistance to SM and RFP were 78.20%,44.14% and 44.68% respectively in 1998,and decreased to 59.62%,27.64% and 21.05%,while the rate of drug resistance to EMB was 14.23% in 1998,and increased to 21.68% in 2008.The rate of drug resistance to INH did not vary on the whole.The rate of drug resistance to one was 35.86% in 1998,and decreased to 31.44% in 2008,while the rate of drug resistance to four was 0.54% in 1998,and increased to 2.08% in 2008.Conclusions The drug resistance of Mycobacterium tuberculosis was in a trend of decline in Xinjiang from 1998 to 2008,although it was more than the mean level of China.The increase of multi-drug resistance of TB calls for special attention.
Key words:Mycobacterium tuberculosis; Extensively drug-resistant tuberculosis; Microbial sensitivity tests
文献标引:李君莲,魏继虎,綦迎成,王泉,李东军,胡忠义,金格勒,刘天剑,刘艳.新疆地区1998至2008年结核分枝杆菌耐药情况分析[J/CD].中华临床医师杂志:电子版,2010,4(7):924-927.
参考文献:
[1] 王甦民.应重视结核病的实验诊断.中华检验医学杂志,2005,28(8):769-770.
[2] 玛依夏提•马合木提,刘来新,马建新,等.新疆卫Ⅴ项目结核病人登记治疗管理分析.地方病通报,2004,19(2):73-74.
[3] 刘宇红,姜广路,赵立平,等.第四次全国结核病流行病学抽样调查-结核分枝杆菌耐药性分析与评价.中华结核和呼吸杂志,2002,25(4):224-227.
[4] 端木宏谨.耐药结核病的流行和监测.中华结核和呼吸杂志,2006,8(8):509-511.
[5] World Health Organization. Anti-tuberculosis drug-resistance in the world.Geneva:WHO,2008:14-18.
[6] 谭云洪,姚孟晖,易松林,等.湖南省2001-2006年结核分枝杆菌耐药性分析.中国预防医学杂志,2008,9(3):193-196.
[7] 丁昊,陈宇炼.1800株结核分枝杆菌对10种抗结核药物耐药分析.南京医科大学学报:自然科学版,2008,10(10):1361-1364.
[8] 胡忠义,蔡慧梅,李来娣,等.上海市1985~1995年结核分支杆菌原发耐药性观察.中华结核和呼吸杂志,2000,23(2):82-84.
[9] 刘相,高官聚,陈海峰,等.2004年至2006年住院肺结核患者结核分支杆菌耐药结果分析.河北医药,2007,11(11):1260-1261.
[10] 贾卫,吴卫东,张伟,等.WHO新疆结核病耐药监测报告.中国防痨杂志,2008,8(4):307.
[11] 接力,许苗.新疆肺科医院5年结核菌培养结果分析.临床肺科杂志,2005,9(5):246.
[12] Singh MM,Chopra KK.MDR-TB current issue.Indian J Tuberc,2004,51(1):1-3.
[13] Alcaide F, Calatayud L, Santin M,et al.Comparative in vitro activities of linezolid,telithromycin,clarithromycin,levofloxacin,moxifloxacin,and four conventional antimycobacterial drugs against Mycobacterium kansasii.Antimicrob Agents Chemother,2004,48(12):4562-4565.[PubMed]
[14] 顾国容,包葵.含克拉霉素的化疗方案治疗耐多药性肺结核临床观察.临床荟萃,2009,4(8):722-723.
[15] Marra F, Marra CA,Moadebi S,et al.Levofloxacin treatment of active tuberculosis and the risk of adverse events.Chest,2005,128(3):1406-1413.[PubMed]
期刊存档









